Int J Pharm

S.No Title & Authors Name Page
Treating Symptoms of Morning Sickness: The First Dual Release Combination of Doxylamine-Pyridoxine
Gideon Koren*, Manon Vrandrick
 Abstract                  View                 Download                 XML

Modified release tablet preparations are sought when there is a need to provide clinical solutions which are not achieved optimally with the standard release products. Nausea and vomiting of pregnancy (NVP) affect most pregnancies. Symptomatic treatment aims to improve woman’s quality of life, and counteract dehydration, electrolyte imbalance, need for hospitalization and attendant risk of maternal and fetal complications. Until recently, the only agent approved by Canada, USA, South Korea. Israel and Singapore has been the delayed release combination of doxylamine and pyridoxine (Diclectin®/ Diclegis®).
All other countries worldwide do not presently have a pregnancy- approved anti emetic drug.
Due to its delayed release properties, Diclectin®/ Diclegis® begins to exert its antiemetic effect 6-8 hours after ingestion, and hence symptom relief may be delayed and necessitate the use of an immediate release medication. In November 2016 the FDA approved Bonjesta®, a novel, dual- release combination of doxylamine and pyridoxine, whereby a rapid release phase is followed by a delayed release phase, thus overcoming the time delay in action of the delayed release combination of doxylamine and pyridoxine.

In this article we review the unique properties of this new drug in the context of other medications where modified- release forms have been effective.

Design, Development and Evaluation of Herbal Transdermal Patches for Anti-Inflammatory Activity
Manjunath Setty M, Surendra Swarnkar, Neha Laxane, Sumit Laxane*
 Abstract                  View                 Download                 XML

In this study, various transdermal matrix patches containing Commiphora mukul of variable combination of ethyl cellulose/polyethylene glycol with enhancer (menthol: limonene) were prepared. The prepared patches were studied with respect to physicochemical characters, drug-excipient interaction, dissolution, skin permeation, stability and in vivo anti-inflammatory studies. The combination of ethyl cellulose and polyethylene glycol produces smooth flexible films. Dissolution and in vitro skin permeation studies revealed that the cumulative amount of drug permeated was decreased as the polyethylene content of the film increased. The film containing enhancer shows greater release as compared to film containing no enhancer. Based on in vitro skin permeation studies, CM4 [PEG/EC, 1:5, menthol (36 ug): limonene (36 ul)], was found to be better formulation as it released a maximum amount of drug. In stability studies, all the formulations were stable with respect to physical properties up to 45 days.

Pharmacy Times are Changing - How Prepared are You?
Rajinder Bains
 Abstract                  View                 Download                 XML

What being a pharmacist means to us: We go to university for 4 years with a final fifth year to put our knowledge into practice. We do all this because of our duty of wanting to serve the public to the best of our ability.

Perceptions of Final Year Pharmacy Students about their Preparedness to Practice Pharmacy and their Career Choices in Sudan
Rugaia Abdelmoneim, Ahmed Awaisu, Nadir Kheir*
 Abstract                  View                 Download                 XML

The article entitled “Perceptions of Final Year Pharmacy Students about their Preparedness to Practice Pharmacy and their Career Choices in Sudan” by Nadir Kheir, et al. (2018) which was published in the International Journal of Pharmacy on September 09, 2018 has been retracted. According to the request of the corresponding author, Nadir Kheir, the article has been retracted from the journal. The authors and Editorial office deeply regret any inconvenience this publication has caused for readers.

Formulation Development and Evaluation of Niosomal Gel of Combined Anti-Fungal Agents
Irene Thomas*, Beena P, Elessy Abraham
 Abstract                  View                 Download                 XML

Miconazole, glucocorticoid antagonist and Terbinafine, Sqalene epoxidase inhibitor are two of the commonly used drug for fungal diseases. In this present work, Miconazole and Terbinafine in combination was formulated as Niosomal gel and evaluated. Niosomes containing both the drugs were prepared by thin film evaporation technique with varying concentration of Nonionic surface active agent, Span 60 and cholesterol. FTIR and DSC study reports confirmed the absence of incompatibilities between the two drugs and the excipients. Five Niosomal formulations were prepared (N1- N5) and evaluated for surface morphology, particle size, PDI, Drug content, entrapment efficiency, Zeta potential, in vitro drug release and TEM analysis. The formulation (N3) containing equal concentration of Span 60 (100 mg) and Cholesterol (100 mg) showed highest yield, drug content and its entrapment efficiency was found to be 91.06%. All the Niosomal dispersions were incorporated into 2% Carbopol gel base to produce five Niosomal gel formulations NG1–NG5. Niosomal gels were evaluated for physical properties, pH, Viscosity, Spreadability, Extrudability, Drug content and in vitro drug release. NG3 was found to be the best formulation as it showed promising qualities of a gel with a maximum release of 84.523% (MCZ) and 85.812% (TBF) after 8 hrs and maximum anti-fungal activity than all the other Niosomal gel formulations. From the antifungal activity carried out, Zone of inhibition of two drugs in combination was found to be greater than the zone inhibition of individual pure drugs indicating the synergistic activity of the drugs. Skin irritation studies were conducted in Egg CAM and all the formulations showed non-irritant reports. Niosomal gel showed good stability at various temperatures. The kinetic data analysis showed that Niosomal gel fits to Higuchi model and follows zero order release by non-fickian super case Ⅱ diffusion. All these findings proved that Niosomal gel containing combined antifungal drugs is more effective than the marketed plain gel containing a single antifungal agent. Since the two drugs are having different mechanism of action they overcome the anti-fungal resistance shown by the organism and broaden the fungal spectrum. Moreover Niosomal gel improves the topical formulation with a high degree of skin permeation and prolongs maintenance of drug by increasing the retention time in the target area at a therapeutic level thereby decreasing the frequency of administration and increasing patient compliance.

Metformin and Urtica pilulifera- Comparable Effects and Similar Actions in Diabetes
Ahed J Alkhatib* and Ilham Ahed Alkhatib
 Abstract                  View                 Download                 XML

The purpose of this editorial is to show our experience in using both metformin and Urtica pilulifera (U. pilulifera) as diabetic therapeutic options. In brief, we would like to give some information about U. pilulifera and metformin.